Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.35 |
| ▸ | HTR3A | P46098 | 3/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744261 | 0.83 | PARP1 (0.33) | PARP1HTR3APARP2 | |
| SCHEMBL3749081 | 0.82 | PARP1 (0.35) | PARP1HTR3APARP2 | |
| SCHEMBL18344061 | 0.78 | HTR3A (0.31) | HTR3A | |
| SCHEMBL3759146 | 0.78 | HRH3 (0.33) | — | |
| SCHEMBL18344138 | 0.77 | EGFR (0.33) | HTR3A | |
| SCHEMBL3748155 | 0.76 | HTR3A (0.33) | PARP1HTR3A | |
| SCHEMBL3751058 | 0.73 | MEN1 (0.35) | — | |
| SCHEMBL3756398 | 0.73 | IRAK4 (0.36) | HTR3A | |
| SCHEMBL18344037 | 0.72 | L3MBTL3 (0.39) | PARP1HTR3A | |
| SCHEMBL18344145 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | PARP1 4719/4885HTR3A 129/4885PARP2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.